Price quotes for Zetia from multiple providers

The lead outside investigator on a crucial trial of two widely used heart drugs said in an e-mail message last July that Merck and Schering-Plough, the companies that make the drugs, were deliberately delaying the release of the trial results “to hide something,” The New York Times reported April 1.
The companies did not release the preliminary results of the trial, called Enhance, until January, almost two years after the trial was finished. When they were finally released, t…

Merck & Co. has received an additional six months of patent protection in the United States for its cholesterol-lowering drug Zocor. The patent, which was due to expire after December 23, 2005, now extends to June 23, 2006. Merck, which achieves annual sales of more than $6 billion with Zocor, is seeking to enhance the Zocor franchise through a partnership with Schering-Plough Corp.

…

A controversy over the cholesterol-fighting medicine Vytorin has spawned at least 33 lawsuits by consumers who are angry over the way Merck and Schering-Plough promoted the medicine to lower low-density lipoprotein, “The …

If you have cholesterol problem and you are continuously ignoring it then it can create serious problems for you. Lipitor which includes pravachol lipitor, lipitor pravachol or lipitor zetia is the best m…

(ezetimibe, Merck and Schering-Plough)
A cholesterol absorption inhibitor for use as an adjunct to diet for reducing elevated total cholesterol, LDL cholesterol, and apo B levels in patients with primary (heterozygous familial and nonfamilial) hypercholesterolemia, either alone or with an HMG-CoA reductase inhibitor. The first d…

Zetia (ezetimibe) has received an expanded approval in combination with diet and fenofibrate for the reduction of total cholesterol and low-density-lipoprotein cholesterol in patients with mixed hyperlipidemia. In the pivotal study, Zetia 10 mg was administ…

Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results, according to a “New York Times” article of Dec. 21.
Partial results of the studies, alluded to in documents on FDA’s website raise questions about whether Zetia can cause liver damage when used long term with other cholesterol drugs…

LegalView announced plans to release a new children’s over-the-counter cough and cold medicine practice area dealing with legal and medical issues surrounding the medication. The practice area is being launched after the U.S. Food and Drug Administration (FDA) released results from a review that found harmful and even deadly side effects exist when treat…

CHICAGO — Fitch Ratings has placed Schering-Plough Corp.’s (Schering-Plough) (NYSE:SGP) ratings on Rating Watch Negative. The action applies to approximately $11.98 billion of outstanding debt.
The Rating Watch reflects Fitch’s concern that Schering-Plough will be unable to reduce leverage, total …

Denver, CO - LegalView recently updated its Heparin information portal to include the latest information on the Baxter Heparin recall that may have caused severe allergic reactions and the deaths of more than 80 patients. Investigating the source of contamination has led U.S. officials to a manufacturing plant in China, where over-sulfated chrondroitin sulfate was reportedly chemically altered to simulate Heparin. …